Study calms pioglitazone bladder cancer concerns

Fears that use of diabetes drug pioglitazone could significantly increase the risk of bladder cancer are unfounded, according to a 10-year epidemiological study.

The findings contradict the five-year interim report of the study, which sparked a TGA warning when it suggested a 1.4 increased risk among patients taking the drug for two or more years.

Sales of pioglitazone,